



pharmaceuticals ltd.

Registered & Corporate Office :

Plot No. 19-111, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills Hyderabad - 500 096.Telangana. INDIA,
Tel : +91-40-6628 8888, Fax : +91-40-2355 1401/402
CIN : L24239AP1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Date: 8th February, 2018

To,
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code:532815

Symbol: SMSPHARMA

Subject: Outcome of the Board Meeting held on 8th February, 2018.

Dear Sir/Madam,

With reference to the above subject, we would like to inform you that the Board of Directors of the Company at their meeting held on today and concluded at 2.50 P.M inter-alia transacted the following items of agenda:

1. Approved the standalone Un-audited Financial Results for the Quarter ended 31st December, 2017 along with Limited Review Report.
2. Approved the appointment of Mr. V.S.Venkatish, Company Secretary and Compliance Officer, with effect from 8th February, 2018.


Accordingly, please find enclosed the following;

1. Standalone Un-audited Financial Results for the Quarter ended 31st December, 2017 along with Limited Review Report.

Please take the above intimation on your records.

Yours Faithfully,

For SMS Pharmaceuticals Limited


Lakshminarayana Tammineedi
Chief Financial Officer

BRIEF PROFILE OF COMPANY SECRETARY

Name : Vudari Satyanarayan Venkatish

Father's Name : Vudari Satyanarayana

Date of Birth : 04-07-1972

Address: : 12-13-829-c-30-A, shridi Sai Nagar, St.No11 Extn,
Keemthi colony, Tarnaka, Secunderabad. Pin; 500017.

Experience :Mr.V.S.Venkatish is Master of Commerce, Bachelor of Laws, and also the Associate Member of the Institute of Company of India, with the Membership No: 21785.He has total experience of above 12 years. He worked as a Company Secretary for the Listed Companies, Unlisted Limited Companies, Private Limited Companies and also with Public Sector Companies like ECIL (Electronic Corporation of India Limited) and has experience dealing with Stock Exchanges, Registrar of Companies and other Statutory Authorities.


SMS PHARMACEUTICALS LIMITED

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months Ended 31st December, 2017

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Nine Months Ended	
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue From Operations	10,371.95	12,728.67	12,606.33	36,362.42	35,186.20
2	Other Income	15.64	112.41	41.87	169.90	78.25
3	Total Revenue (1+2)	10,387.59	12,841.08	12,648.20	36,532.32	35,264.45
4	Expenses					
	(a) Cost of materials consumed	7,095.47	9,854.32	10,474.45	24,626.64	26,255.79
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods work-in-progress and stock-in trade	(1,135.52)	(1,219.24)	(2,026.15)	(815.74)	(2,546.68)
	(d) Employee Benefits Expense	814.27	775.37	686.48	2,304.85	1,896.53
	(e) Finance costs	402.21	426.76	419.53	1,180.03	1,223.32
	(f) Depreciation and amortisation expense	499.07	496.72	482.75	1,489.36	1,439.85
	(g) Other expenses	1,083.26	1,253.17	1,381.49	3,636.18	3,661.53
	Total Expenses - (a to g)	8,758.76	11,587.10	11,418.55	32,421.32	31,930.34
5	Profit before Exceptional and Extraordinary Items and Tax (3-4)	1,628.83	1,253.98	1,229.65	4,111.00	3,334.11
6	Exceptional items	-	-	-	-	-
7	Profit before Extraordinary Items and Tax (5-6)	1,628.83	1,253.98	1,229.65	4,111.00	3,334.11
8	Extraordinary Items	-	-	-	-	-
9	Profit before Tax (7-8)	1,628.83	1,253.98	1,229.65	4,111.00	3,334.11
10	Tax Expenses					
	(1) Current Tax (MAT)	350.00	276.64	100.00	891.64	550.00
	(2) Deferred Tax	64.49	40.18	168.84	144.75	468.88
11	Net Profit / (Loss) for the Period (9-10)	1,214.34	937.16	960.81	3,074.61	2,315.23
12	Other Comprehensive Income (OCI): Items that will not be reclassified to profit or Loss: Remeasurement of post-employment benefit obligation (net of tax)	(6.54)	(6.54)	-	(23.15)	(8.39)
		(6.54)	(6.54)	-	(23.15)	(8.39)
13	Total comprehensive income for the period (11+12)	1,207.80	930.62	960.81	3,051.46	2,306.84
14	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52	846.52
15	Other Equity					
16	Earning Per Equity Share of Re.1/ each (not annualised)	1.43	1.11	1.14	3.63	2.73
	(a) Basic					
	(b) Diluted					



Notes:


- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 08th February, 2018 and have been approved by the Board of Directors at its meeting held on 08th February, 2018.
- 2 Results for the quarter ended 31st December, 2017 were subjected to 'Limited Review' by the Statutory Auditors.
- 3 The Company has adopted Indian Accounting Standards (IND-AS), prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, with effect from 01st April, 2017, with transition date April 1, 2016. The unaudited Standalone Financial Results has been prepared by the Company in accordance with IND AS notified under the Company's (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016. The financial results have been prepared in accordance with recognition and measurement principles laid down in IND AS 34 Interim Financial Reporting.

The Ind AS compliant financial results pertaining to quarter ended 31st December, 2016 has not been subjected to limited review. However, the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs and the same was subjected to review by the statutory auditors under 'IGAAP'.

A reconciliation of financial results as reported under Previous Indian GAAP (referred as "IGAAP") and IND-AS is summarised below:

Particulars	(Rs. In Lakhs)	
	Quarter ended 31.12.2016	Nine Months ended 31.12.2016
Net Profit as per previous GAAP (Indian GAAP)*	960.49	2,310.81
Ind AS adjustments:		
Actuarial loss on employee defined benefit funds recognised in Other Comprehensive Income	-	12.83
Others	(2.41)	(14.72)
Deferred taxes on Ind AS adjustments	2.72	6.31
Net Profit as per Ind AS	960.81	2,315.23
Other Comprehensive Income, net of Income Tax	-	(8.39)
Total comprehensive Income for the period	960.81	2,306.84

- 4 These results do not include Ind AS compliant results for the previous year ended 31st March, 2017 as the same is not mandatory as per SEBI Circular dated 5th July, 2016.



- 5 In accordance with the requirements of Ind AS18, revenue from operations for the quarter ended 31st December,2017 is shown net of Goods and Services Tax (GST). However, net sales for the corresponding quarter and previous year Nine Months ended are shown inclusive of excise duty. Nine Months period ended 31st December, 2017 includes excise duty upto 30th June,2017. The following additional information is being provided to facilitate better clarity.


(Rs.in Lakhs)

Particulars	Quarter Ended			Nine Months ended	
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016
Revenue from Operations	11,241.84	14,909.96	12,632.21	39,413.59	35,212.07
GST Recovered	869.89	2,181.28	-	3,051.17	-
Excise Duty Recovered			269.34	255.17	703.73
Revenue from Operations excluding GST/Excise Duty	10,371.95	12,728.67	12,362.87	36,107.25	34,508.35

- 6 The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 7 As per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
- 8 Figures of previous period have been regrouped / rearranged wherever necessary.

For SMS Pharmaceuticals Limited

Ramesh Babu Potluri
Chairman and Managing Director



Place: Hyderabad

Date : 08-02-2018



Limited Review Report

To
The Board of Directors
SMS PHARMACEUTICALS LIMITED
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS PHARMACEUTICALS LIMITED ("the Company"), for the quarter ended 31st December 2017 ("the statement"), being submitted by the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

As stated in Notes of financial statement, we have not performed a review of the figures relating to the corresponding quarter ended 31st December, 2016 including the reconciliation of net profit for the quarter ended 31st December, 2016 between the previous GAAP and the Indian Accounting Standards ("Ind AS")

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 08-02-2018

For Suryanarayana & Suresh.,
Chartered Accountants
Reg. No.006631S



Nagendra Rao
Nagendra Rao
Partner
M. No. 227679